Regeneron Pharmaceuticals (NASDAQ: REGN) is a $5.54 billion biopharmaceutical firm with one marketed product and numerous late-stage drugs in its pipeline with several FDA approval filings scheduled for the second half of 2011. In addition, REGN has an...